Great Information, Real Community, Better Living.
 Main Page
 MedTech News
Tech & Innovation
Living With a Device
 Education Center
Diagnostic Tests
Women's Health
Online Resources
Video Library
Dr. Christopher Kwolek  MedTech  Hero™
Dr. Christopher Kwolek:
Pioneering New Blood Clot Treatments.
About Heroes
 Join the Discussion in  Our Forums
MedTech1 Forums
 Advocacy Center
Contact Congress
Find a Patient Group
 Bookmark Us
Search the Body1 Network
August 08, 2020  
MEDTECH NEWS: Technology & Innovation

  • Print this Article
  • Email this Article
  • Links/Reprints
  • Prospective Colorectal Cancer Treatment Drug

    MultiCell Technologies Announces Prospective Colorectal Cancer Treatment Drug

    February 26, 2007


    MultiCell Technologies, Inc.
    Dr. Stephen Chang, CEO
    [email protected]

    SAN DIEGO--(BUSINESS WIRE)--MultiCell Technologies, Inc., developing first-in-class drugs based on advanced immune system modulation technologies, announced today it has reached a developmental milestone to advance its colorectal cancer lead therapeutic candidate to preclinical development status. MCT-475 is indicated as a prospective treatment for metastatic colorectal cancer, the third leading cause of death among both men and women in the United States. MCT-475 is a patent pending antigen-presenting immunoglobulin therapeutic which is intended to be co-administered with MCT-465, a Toll-like Receptor (TLR) agonist.

    “Previously we demonstrated that co-administration of MCT-465 with our patent pending antigen-presenting immunoglobulin therapeutic IgNP prototype completely destroyed tumors, and prevented mortality and recurrence in animal models,” said Dr. Stephen Chang, President and CEO of Multicell Technologies. “MCT-475 is designed to activate the adaptive immune system to target unique structural motifs located on the surface of human metastatic colorectal cancer cells, while MCT-465 is designed to activate the innate immune system through TLR signaling. Working together, MCT-475 and MCT-465 stimulate the body’s immune system to target and kill metastatic colorectal cells.”

    Colorectal cancer is the third most common cancer in both men and women in the United States, and remains the third leading cause of death from cancer in the United States. The American Cancer Society estimates that about 145,000 new cases of colorectal cancer were reported in 2005.

    According to the World Health Organization's April 2003 report on global cancer rates more than 940,000 new cases of colorectal cancer, and nearly 500,000 deaths are reported worldwide each year. The overall 5-year survival rate from the various types of colorectal cancer is approximately 60%, whereas for metastatic colorectal cancer, the 5-year survival rate is about 5%.

    Risk factors for metastatic cancer include age, a diet rich in fat and cholesterol, inflammatory bowel disease, and genetic predisposition. If detected early, colorectal cancer is curable by surgery. Chemotherapy can prolong survival in patients where the disease has metastasized and reached the lymph nodes.

    MultiCell is an innovator in the science of modulating the human immune system with unique platform technologies, focusing on the development of breakthrough drugs to treat serious diseases, including multiple sclerosis, type-1 diabetes, influenza, and cancer.

    About MultiCell Technologies, Inc.

    MultiCell Technologies, Inc. is an integrated biopharmaceutical company committed to the development of breakthrough therapeutics based on a portfolio of therapeutic candidates and patented drug development technology. MultiCell's drug development program is focused on modulation of the immune system.

    MultiCell's therapeutic pipeline includes drug candidates some of which are in various advanced stages of human clinical trials. These therapies include:

    MCT-125 for the treatment of chronic fatigue in MS patients.
    MCT-175 for the treatment of relapsing-remitting MS.
    MCT-275 for the treatment of type-1 diabetes.
    MCT-465 an adjuvant therapy for the treatment of virus infection and cancer.
    MCT-475 for the treatment of colorectal cancer.

    The Company also holds unique cell-based technology for use in drug discovery screening applications, and is a leading producer of the cell lines needed by the biotechnology industry to develop new drugs. For more information about MultiCell Technologies, please visit

    Last updated: 26-Feb-07


  • Add Comment
    Interact on Medtech1

    Discuss this topic with others.
    Feature Archives

    Web Technology to Offer Further Mental Health Support

    Sweat Powers Tattoo Biobatteries While You Exercise

    Activity Trackers Could be Beneficial for Older Adults

    Diseases Diagnosed by 'Smart' Holograms

    Fruit flies make good stand-ins for humans in diabetes treatment tests

    Next 5 Features ...

    More Features ...
    Related Content
    Colorectal Cancer

    Good News: Improved Prognosis for Patients with Esophageal Cancer

    Resistant Ovarian Cancer Responds to Aspirin Derivative

    During Cancer Treatment, 'Quality Of Life' Therapy Improves Health

    Ground-Breaking New Method To 'Starve' Cancer Cells

    More Features ...
    Home About Us Press Jobs Advertise With Us Contact Us
    © 2020 Body1 All rights reserved.
    Disclaimer: The information provided within this website is for educational purposes only and is not a substitute for consultation with your physician or healthcare provider. The opinions expressed herein are not necessarily those of the Owners and Sponsors of this site. By using this site you agree to indemnify, and hold the Owners and Sponsors harmless, from any disputes arising from content posted here-in.